Its proprietary S-TIR-Platform™ is available for licensing on a target-by-target basis. With its scientifically validated Proof of Concept (PoC), it offers the chance to rapidly develop new vaccines from design to PoC within 9 to 12 months. The lead candidate OQR200 is available for licensing: It triggers an active, reversible and appropriate immune response without side effects. A pre-clinical information package will be made available under CDA. Outstanding results on scientific research are available since September 2017.